QBM076

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

COPDColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

Phase 1

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

CompletedNCT02890069

Novartis PharmaceuticalsColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma

Start: 2016-10-14End: 2022-02-22Updated: 2023-01-11

Phase 2

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

TerminatedNCT01972776

Novartis PharmaceuticalsCOPD

Start: 2013-11-30End: 2015-05-31Updated: 2016-03-24

Related Papers

Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells

Cancer Cell International2024-05-243 citations